Special Issue "Nuclear Medicine for Prediction of Therapy Efficacy and Therapeutic Evaluation in Oncology"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2020).
Interests: FDG-PET; Immuno-PET; hematology; multiple myeloma; lymphoma; theranostics; radionuclide therapy; therapeutic evaluation; radiomics
2. Nuclear Medicine Department, University Hospital, 44093 Nantes, Franc
Interests: nuclear oncology; radionuclide therapy; radioimmunotherapy; PET; theranostics; radiomics; therapeutic evaluation
The field of molecular imaging has been revolutionized in the last 20 years by the development of nuclear medicine and particularly positron emission tomography (PET). This non-invasive molecular imaging technique enables direct and longitudinal in vivo studies of critical molecular processes. It has undoubtedly changed the landscape of cancer management, providing a whole-body method of assessing tumor heterogeneity, through the use of multiple radiopharmaceuticals, each providing different information or through the information derived from the uptakes’ analysis of a tracer such as 18F-fluoro-deoxyglucose (FDG). This imaging technique is continually proving its ability and potential to characterize tumor status for personalized medicine, such as monitoring response to treatment or assessing tumor targeting of the drug.
This Special Issue aims to give a comprehensive overview of the role of nuclear medicine in cancer management, in providing essential information in clinical practice for treatment decision-making strategies, to better select patients with poor prognosis for more intensive therapy or those eligible for targeted therapy. This issue will highlight recent significant accomplishments of PET applications with both 18-fluorodeoxyglucose (FDG) and non-FDG tracers regarding therapeutic evaluation and prediction of therapies’ efficacy moreover outlining the challenges of current theranostic developments.
Prof. Françoise Kraeber-Bodéré
Dr. Clément Bailly
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- oncological imaging
- therapeutic evaluation
- solid tumors
- new tracers